← All trials
NCT06208657
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2024
- Primary completion
- Dec 31, 2030
- Completion date
- Dec 31, 2035
- First posted
- Jan 17, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 82
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Australian & New Zealand Childhood Hematology & Oncology GroupLead sponsor
- Kazia Therapeutics LimitedCollaborator
- Day One Biopharmaceuticals, Inc.Collaborator
- C17 CouncilCollaborator
- Medical Research Future Fund (MRFF)Collaborator
- University of TorontoCollaborator
- Bristol-Myers SquibbCollaborator
- Stand Up To CancerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.